Background: SerpinB7 is a serine proteinase inhibitor of the ovalbumin like B clade of serpins. It was first discovered in a search for agents responsible for thrombopoiesis, and maturation of megakaryocytes. SerpinB7 was identified as a protein that increased acetylcholine esterase stimulation from bone barrow progenitor cells, and injection of SerpinB7 in mice induced a 40% increase in platelets compared to controls. Shortly thereafter, in a search for kidney specific genes, SerpinB7 was described as a protein specific to mesangial cells, and was named megsin to indicate the tissue specificity of the protein. SerpinB7 message was found to be elevated in diabetic nepropathy and in IgA nepropathy, and overexpression of megsin in transgenic mice led to hyperproliferation of mesangial cells, glomerular lesions, and immune complex deposition. The megsin overexpression mouse is thought of as a model for diabetic nepropathy, and a polymorphism in megsin in the Chinese population is thought to confer susceptibility to IgA nepropathy. Most of the work on SerpinB7 has been in the kidney, since early publications indicated that the protein was specific to the kidney, but the human epidermoid carcinoma cell line A431 also produces SerpinB7, as do many other human cell lines. Little is known abut the serine proteinase capacity of SerpinB7. The initial publication showed that some serine protease activity was inhibited, but did not identify the specificity. The original sequence described was 380 amino acids in length, with predicted mass of 42.9 kDa and pI of 6.35.
Description: Rabbit polyclonal to SerpinB7
Immunogen: KLH conjugated synthetic peptide derived from SerpinB7
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 43 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
